Dr Phil Reilly on newborn screening: past, present and future

P.ReillyP.Reilly
W.GreeneW.Greene
BulletArticle
Rare Diseases C-Suite Perspectives Leaders In Conversation Newborn Screening
Chia sẻ điều này:
Sao chép liên kết
Dr Phil Reilly on newborn screening: past, present and future

Dr Phil Reilly is a physician, clinical geneticist, biotech entrepreneur, venture capitalist and author with deep experience in rare disease diagnostics, including newborn screening (NBS). In this Q&A with Will Greene, Healthcare Engagement Manager and Project Strongbow Co-Lead at Roche Diagnostics Asia Pacific, we learn more about the history and future of NBS technologies in the United States and around the world.

Chia sẻ điều này:
Sao chép liên kết

Xem thêm về cùng chủ đề

Emerging haemophilia therapies highlight a need for quality diagnostics

Newborn screening in Taiwan: Q&A with Dr Yin-Hsiu (Nancy) Chien

Chủ đề được đề xuất

SequencingRED 2020Rare Diseases
Đọc tiếp theo
‘Real world evidence’ and clinical labs: a brief introduction
  • Healthcare Transformation, Management, Operations, Population Health Management
‘Real world evidence’ and clinical labs: a brief introduction
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
  • Disease Area, Healthcare Transformation, Histopathology, Leaders In Conversation, Management, Oncology, Operations
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
3 steps to mitigate the impact of interference
  • Clinician Engagement, Coagulation, Disease Area, Management
3 steps to mitigate the impact of interference
A guide to balancing quality, speed and cost
  • Operational Excellence, Operations
A guide to balancing quality, speed and cost
Scroll to Top